Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
MWN-AI** Summary
Iridex Corporation, a leading provider of innovative laser-based medical systems, recently announced a significant study published in *Translational Vision Science & Technology* that focuses on the thermal dynamics of transscleral laser treatments for glaucoma. Conducted by Dr. Tomas M. Grippo and his team at the Grippo Glaucoma & Cataract Center in Buenos Aires, the study introduced a comprehensive computer model that quantitatively compares the thermal effects of continuous-wave transscleral cyclophotocoagulation (CW-TSCPC) and MicroPulse® technology (MicroPulse TLT).
Utilizing advanced Monte Carlo computer simulations, the researchers examined how each laser technique affects the ciliary body. The results revealed that CW-TSCPC creates a broader zone of tissue heating, with temperatures exceeding 100°C for about 2.2 seconds, while MicroPulse TLT maintains a smaller thermal zone (0.6-1.2 mm) and shorter peak temperatures, never exceeding 100°C. The study noted a more uniform heat distribution with MicroPulse TLT compared to CW-TSCPC.
Dr. Grippo highlighted that this computational analysis provides fresh insights, linking thermal dynamics to the safety and effectiveness documented in existing literature. He emphasized the potential for refining these laser treatments, suggesting their roles could evolve for various stages of glaucoma, from refractory cases to earlier interventions.
Iridex’s CEO, Patrick Mercer, reinforced the company's commitment to enhancing evidence-based innovation in glaucoma care. By deepening the understanding of how these laser techniques interact with ocular tissues, Iridex aims to optimize treatment and safety, expanding clinical options for both CW-TSCPC and MicroPulse TLT in modern glaucoma management. This study positions Iridex favorably in the evolving ophthalmology market, showcasing their commitment to advancing patient care through innovative technology.
MWN-AI** Analysis
Iridex Corporation (Nasdaq: IRIX) recently announced a pivotal study that enhances the clinical foundation and market potential of its MicroPulse® technology and Continuous-Wave Laser (CW-TSCPC) for glaucoma treatment. Published in *Translational Vision Science & Technology*, the study, led by Dr. Tomas M. Grippo, provides a cutting-edge quantitative analysis of the thermal dynamics associated with both laser treatment methods.
The study’s findings reveal critical differences in thermal effects caused by the two techniques. While CW-TSCPC produced a larger thermal zone, rising above 100°C, MicroPulse TLT demonstrated a superior safety profile with lower peak temperatures and a more uniform heat distribution, suggesting it may be better suited for earlier intervention cases in glaucoma treatment. This evidence reinforces Iridex's commitment to advancing laser treatments that prioritize patient safety and efficacy.
Given the crucial insights provided by this research, investors should take note of the potential implications for Iridex's market position. With increased understanding of these technologies' safety and effectiveness, Iridex could enhance its product offerings and potentially expand its treatment applications, leading to broader market adoption. Moreover, as glaucoma remains a significant global health issue, enhanced treatment modalities may attract increased physician adoption and, subsequently, growth in revenue streams.
As Iridex continues to harness its research capabilities to refine and promote its technology, investors should consider its strategic focus on evidence-based innovation as a strong indicator of future success. Therefore, retaining an optimistic outlook on IRIX could prove wise, particularly as the company’s advancements in laser treatments create new clinical opportunities and broaden its market reach. Now may be an opportune time for investors to evaluate or adjust their positions in Iridex based on these promising developments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published study in Translational Vision Science & Technology (TVST) examining the thermal dynamics of transscleral laser treatments for glaucoma. 1
Led by Tomas M. Grippo, MD, of the Grippo Glaucoma & Cataract Center (Buenos Aires, Argentina), the study provides the first quantitative computer model comparing the thermal tissue effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and transscleral laser therapy using MicroPulse ® technology (MicroPulse TLT) with Iridex’s Cyclo G6 ® Laser, G-Probe ® and MicroPulse P3 ® delivery devices.
Using advanced Monte Carlo computer simulations, the authors modeled how each technique heats the ciliary body and quantified temperature peaks, duration, and thermal spread. The modeling revealed that CW TSCPC produced a 2 mm-wide zone of tissue heating with temperatures exceeding 100°C for approximately 2.2 seconds. MicroPulse TLT generated a smaller 0.6-1.2 mm thermal zone and shorter duration peak temperatures, remaining below 100°C. Additionally, MicroPulse TLT showed a more uniform heat distribution than CW-TSCPC.
Dr. Grippo explained, “Our study uses a computational model to analyze heat behavior in the ciliary body during CW-TSCPC and MicroPulse TLT treatments. By linking these findings to the safety, effectiveness, and mechanisms of action described in the literature for both treatments, we can reinterpret existing clinical evidence from a fresh perspective. This approach strengthens our understanding and conceptual framework for these techniques and provides insights that may help refine both laser procedures for improved patient outcomes.”
The authors concluded that both techniques share a thermal continuum, and with further optimization, each may evolve to serve distinct but complementary roles from refractory glaucoma to earlier intervention cases.
“Dr. Grippo’s work underscores Iridex’s commitment to advancing evidence-based innovation in glaucoma care,” said Patrick Mercer, CEO of Iridex Corporation. “By deepening our scientific understanding of how these two transscleral laser approaches interact with ocular tissues, we can continue to improve treatment optimization and safety creating broad clinical opportunities for both CW-TSCPC and MicroPulse TLT in modern glaucoma management.”
The article is available in Translational Vision Science & Technology .
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse ® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com .
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
Media Contact
Joan Stauffer
jstauffer@iridex.com
For more information about Iridex technologies, visit www.iridex.com .
Iridex, the Iridex logo, MicroPulse ® , the MicroPulse logo, Cyclo G6, MicroPulse P3 ® , and G-Probe ® are registered trademarks of Iridex. ©2025 Iridex Corporation. All rights reserved.
References
- Grippo TM, LaMarche K, Davreux AM, Stauffer J, Stacey S, Arnold K. Thermal tissue modeling of the ciliary body with continuous wave transscleral cyclophotocoagulation and transscleral laser therapy using micropulse technology . Transl Vis Sci Technol . 2025;14(11):32.
FAQ**
How do the findings from the study on thermal dynamics of laser treatments enhance the market position of IRIDEX Corporation IRIX in the ophthalmic medical devices sector?
What are the potential implications for patient outcomes that may arise from the advancements in CW-TSCPC and MicroPulse TLT techniques investigated by IRIDEX Corporation IRIX?
How does the new study on transscleral laser treatments support IRIDEX Corporation IRIX’s commitment to evidence-based innovation in glaucoma care?
What competitive advantages might IRIDEX Corporation IRIX gain by optimizing the thermal management of both CW-TSCPC and MicroPulse TLT in future product developments?
**MWN-AI FAQ is based on asking OpenAI questions about IRIDEX Corporation (NASDAQ: IRIX).
NASDAQ: IRIX
IRIX Trading
-6.43% G/L:
$1.31 Last:
14,431 Volume:
$1.38 Open:
